Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors.

ABSTRACT: Interleukin-17 inhibitors are effective in psoriasis; however, they are associated with an increased risk of infections, particularly oral candidiasis, and new-onset/flares of inflammatory bowel disease. This study aimed to identify predictive markers for these adverse events and to describe the functional immune response in patients treated with interleukin-17 inhibitors using a whole-blood stimulation system (TruCulture®). Patients with psoriasis initiating an interleukin-17 inhibitor (n = 36) or adalimumab (n = 24) were enrolled. Patients attended visits at baseline, week 12, and week 52, during which skin and mucosal swabs, and faecal and blood samples were collected. Baseline oral Candida albicans colonization with no clinical symptoms was associated with an increased risk of oral can

SUBMITTER: Schwarz CW 

PROVIDER: S-EPMC12376385 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature